Becton Dickinson and Co (BDX) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 2.4% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 33,951 shares of the medical instruments supplier’s stock after selling 838 shares during the period. Amalgamated Bank’s holdings in Becton Dickinson and were worth $8,861,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BDX. Alps Advisors Inc. grew its position in Becton Dickinson and by 35.3% during the second quarter. Alps Advisors Inc. now owns 1,307 shares of the medical instruments supplier’s stock valued at $313,000 after purchasing an additional 341 shares in the last quarter. Virginia Retirement Systems ET AL purchased a new position in Becton Dickinson and during the second quarter valued at approximately $4,815,000. KBC Group NV grew its position in Becton Dickinson and by 38.2% during the second quarter. KBC Group NV now owns 77,091 shares of the medical instruments supplier’s stock valued at $18,468,000 after purchasing an additional 21,319 shares in the last quarter. Sei Investments Co. grew its position in Becton Dickinson and by 375.5% during the second quarter. Sei Investments Co. now owns 142,450 shares of the medical instruments supplier’s stock valued at $34,127,000 after purchasing an additional 112,492 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new position in Becton Dickinson and during the second quarter valued at approximately $615,000. 85.19% of the stock is currently owned by hedge funds and other institutional investors.

NYSE BDX opened at $234.44 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $65.70 billion, a price-to-earnings ratio of 21.29, a price-to-earnings-growth ratio of 1.69 and a beta of 1.21. Becton Dickinson and Co has a 12-month low of $209.91 and a 12-month high of $265.87.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The business had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the company earned $2.40 earnings per share. Becton Dickinson and’s revenue for the quarter was up 39.0% on a year-over-year basis. As a group, analysts anticipate that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.31%. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.75. The ex-dividend date is Friday, December 7th. Becton Dickinson and’s payout ratio is presently 27.25%.

In other news, SVP Charles R. Bodner sold 2,080 shares of the business’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $245.83, for a total value of $511,326.40. Following the completion of the sale, the senior vice president now directly owns 4,497 shares in the company, valued at $1,105,497.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy M. Ring sold 42,000 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the completion of the sale, the director now owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The disclosure for this sale can be found here. Insiders sold 81,795 shares of company stock valued at $19,571,318 over the last 90 days. 1.00% of the stock is owned by corporate insiders.

A number of research firms have issued reports on BDX. Wells Fargo & Co lifted their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Piper Jaffray Companies reduced their target price on shares of Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, November 6th. Barclays began coverage on shares of Becton Dickinson and in a research note on Monday, October 15th. They issued an “equal weight” rating and a $278.00 target price for the company. KeyCorp lifted their target price on shares of Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a research note on Thursday, November 8th. Finally, Deutsche Bank began coverage on shares of Becton Dickinson and in a research note on Thursday. They issued a “buy” rating and a $280.00 target price for the company. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus target price of $255.53.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/becton-dickinson-and-co-bdx-shares-sold-by-amalgamated-bank.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Do closed-end mutual funds pay dividends?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply